跳至主要内容
临床试验/IRCT20170311033004N3
IRCT20170311033004N3尚未招募2 期

Evaluation of adjunctive therapy of seeds alkaloids of Peganum harmala in the treatment of mild to moderate depression

Iranian academic center for education culture and research0 个研究点目标入组 68 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
68

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 65 years(—)
性别
All

入选标准

  • ability to read, understating and sign the informed consent form and the study procedures
  • male or female aged 18–65 years without any previous diagnosis of other mental disorders such as bipolar disorder, psychosis, primary anxiety disorder, and substance abuse or dependence disorder
  • reporting the Hamilton Depression Rating Score (HAMD) score above 14
  • agreed to use suitable family planning methods during the study and three months afterward
  • non-smoking
  • not being pregnant
  • under only SSRIs antidepressant regimen

排除标准

  • they have a current diagnosis of other mental disorders including bipolar disorder, psychosis, primary anxiety disorder, and substance abuse or dependence disorder
  • pregnancy and breastfeeding
  • taking antidepressant except for SSRIs, mood stabilizer, or antipsychotic drug
  • chemotherapy or other medications known to produce mood changes
  • sensitivity to harmala alkaloids
  • emerging serious adverse effects with the alkaloids

研究者

发起方
Iranian academic center for education culture and research

相似试验